Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06936449 · ClinicalTrials.gov registry record

Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array

A clinical trial of Sensorineural Hearing Loss and Bilateral Hearing Loss, sponsored by Cochlear.

Recruiting
Registry status
19
Enrollment target
3
Study locations

NCT06936449: Recruiting study of Sensorineural Hearing Loss and Bilateral Hearing Loss, sponsored by Cochlear.

NCT06936449 is a study of Sensorineural Hearing Loss and Bilateral Hearing Loss that is actively recruiting participants, run by Cochlear. The registered enrollment target is 19 participants, below the 129-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06936449, a study of Sensorineural Hearing Loss and Bilateral Hearing Loss, is actively recruiting participants, sponsored by Cochlear.

RECRUITING
Registry status
19 participants
Enrollment target
3
Study locations

Study Summary

A long-term follow-up of Cochlear's cochlear implant electrode array which passively elutes dexamethasone for a defined period of time to help reduce inflammatory responses.

Interventions

  • DEVICE CI632D
  • DEVICE CI632

Study Locations (3)

Colorado

  • Rocky Mountain Ear Center - Englewood

Iowa

  • University of Iowa - Iowa City

Ohio

  • University Hospitals Cleveland - Cleveland

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2025-05-05
Est. Completion 2028-03
Cochlear

34 total trials

What NCT06936449 shows while recruiting

NCT06936449 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 129-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Sensorineural Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which CI632D is the first listed.

NCT06936449 reports a single indexed study location in Colorado, Iowa, Ohio.

Frequently Asked Questions

What is clinical trial NCT06936449 about?

NCT06936449 is a clinical study titled "Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array". A long-term follow-up of Cochlear's cochlear implant electrode array which passively elutes dexamethasone for a defined period of time to help reduce inflammatory responses.

What is the current status of trial NCT06936449?

This trial is currently recruiting. The enrollment target is 19 participants. The study started on 2025-05-05. Estimated completion is 2028-03.

What conditions does trial NCT06936449 study?

This clinical trial studies the following conditions: Sensorineural Hearing Loss, Bilateral Hearing Loss.

What interventions are being tested in trial NCT06936449?

The interventions under investigation include: CI632D (DEVICE), CI632 (DEVICE).

Who is sponsoring clinical trial NCT06936449?

This trial is sponsored by Cochlear, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06936449 being conducted?

This trial has 3 study locations across Colorado, Iowa, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sensorineural Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06936449's enrollment target sits among peer trials

19 12th of 13 higher than 2 of 13 other Sensorineural Hearing Loss trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sensorineural Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06936449, the US trial registry maintained by the National Library of Medicine. NCT06936449 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.